Clinical Efficacy of Tobramycin Dexamethasone+Pranoprofen Eye Drops on Endophthalmitis in Cataract Patients Complicated with Diabetes Mellitus after Intraocular Lens Implantation.

IF 0.7 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Nigerian Journal of Clinical Practice Pub Date : 2024-12-01 Epub Date: 2025-03-04 DOI:10.4103/njcp.njcp_565_24

J Wang, H X Fu, J Xu, C Chen, Q Qin, Z G Jing, N M Chen, L Lu

{"title":"Clinical Efficacy of Tobramycin Dexamethasone+Pranoprofen Eye Drops on Endophthalmitis in Cataract Patients Complicated with Diabetes Mellitus after Intraocular Lens Implantation.","authors":"J Wang, H X Fu, J Xu, C Chen, Q Qin, Z G Jing, N M Chen, L Lu","doi":"10.4103/njcp.njcp_565_24","DOIUrl":null,"url":null,"abstract":"Background: There is little research on the anti-inflammatory efficacy and safety of tobramycin dexamethasone+pranoprofen eye drops in treating endophthalmitis.Aim: To appraise the efficacy and safety of tobramycin dexamethasone+propranolofen eye drops in the treatment of endophthalmitis.Methods: The degree of corneal edema, foveal thickness, score of anterior chamber (AC) flares, best corrected visual acuity (BCVA), fasting blood glucose, inflammatory indexes of serum and aqueous humor, and adverse reactions were observed every week.Results: After the intervention with tobramycin dexamethasone+pranoprofen eye drops, corneal edema and foveal thickness reduced, BCVA improved, and the inflammatory markers in serum and aqueous humor decreased. Moreover, the incidence of adverse reactions in the tobramycin dexamethasone+pranoprofen group was lower than that in the control group and the fluorometholone group (P < 0.05).Conclusion: Tobramycin dexamethasone+pranoprofen eye drops can inhibit inflammation better, recover vision faster, and make the incidence of adverse reactions lower in treating cataract patients complicated with DM developing endophthalmitis induced.","PeriodicalId":19431,"journal":{"name":"Nigerian Journal of Clinical Practice","volume":"27 12","pages":"1372-1380"},"PeriodicalIF":0.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nigerian Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/njcp.njcp_565_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There is little research on the anti-inflammatory efficacy and safety of tobramycin dexamethasone+pranoprofen eye drops in treating endophthalmitis.

Aim: To appraise the efficacy and safety of tobramycin dexamethasone+propranolofen eye drops in the treatment of endophthalmitis.

Methods: The degree of corneal edema, foveal thickness, score of anterior chamber (AC) flares, best corrected visual acuity (BCVA), fasting blood glucose, inflammatory indexes of serum and aqueous humor, and adverse reactions were observed every week.

Results: After the intervention with tobramycin dexamethasone+pranoprofen eye drops, corneal edema and foveal thickness reduced, BCVA improved, and the inflammatory markers in serum and aqueous humor decreased. Moreover, the incidence of adverse reactions in the tobramycin dexamethasone+pranoprofen group was lower than that in the control group and the fluorometholone group (P < 0.05).

Conclusion: Tobramycin dexamethasone+pranoprofen eye drops can inhibit inflammation better, recover vision faster, and make the incidence of adverse reactions lower in treating cataract patients complicated with DM developing endophthalmitis induced.

查看原文本刊更多论文

妥布霉素地塞米松+普萘洛芬滴眼液治疗白内障合并糖尿病人工晶状体植入术后眼内炎的临床疗效

背景：妥布霉素地塞米松+普萘洛芬滴眼液治疗眼内炎的抗炎疗效和安全性研究较少。目的：评价妥布霉素地塞米松联合心得洛芬滴眼液治疗眼内炎的疗效和安全性。方法：每周观察两组患者角膜水肿程度、角膜中央凹厚度、前房耀斑评分、最佳矫正视力、空腹血糖、血清及房水炎症指标及不良反应情况。结果：妥布霉素地塞米松+普萘洛芬滴眼液干预后，角膜水肿减轻，角膜中央窝厚度减轻，BCVA改善，血清及房水炎症指标降低。妥布霉素地塞米松+普萘洛芬组不良反应发生率低于对照组和氟美洛酮组（P < 0.05）。结论：妥布霉素地塞米松+普萘洛芬滴眼液治疗白内障合并糖尿病并发眼内炎患者能较好地抑制炎症，恢复视力较快，不良反应发生率较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nigerian Journal of Clinical Practice MEDICINE, GENERAL & INTERNAL-

CiteScore

1.40

自引率

0.00%

发文量

275

审稿时长

4-8 weeks

期刊介绍： The Nigerian Journal of Clinical Practice is a Monthly peer-reviewed international journal published by the Medical and Dental Consultants’ Association of Nigeria. The journal’s full text is available online at www.njcponline.com. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. The journal makes a token charge for submission, processing and publication of manuscripts including color reproduction of photographs.